UNITED STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549



FORM 10-K/A

(Amendment No. 1)

(Mark One)

☒   ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended September
30, 2015

☐TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             
to.

Commission File No: 333-88480

OHR PHARMACEUTICAL,
INC.

(ExactName of Registrantas Specified in its Charter)



|Delaware                                                      |  | 46-5622433                          
|------------------------------------------------------------- |  | ------------------------------------
|(State or Other Jurisdiction ofIncorporation or Organization) |  | (I.R.S. Employer Identification No.)



800 Third Ave, 11th FloorNew York, NY 10022(Address of Principal Executive Offices)

212-682-8452Registrant’s telephone number, including area code

Securities registered under Section 12(b)
of the Exchange Act: Common Stock, par value $0.0001 per share
Name of each exchange on which registered: NASDAQ Capital Market
Securities registered under to Section 12(g) of the Exchange Act: None

Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐
No ☒

Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐
No ☒

Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). Yes ☒
No ☐

Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to
the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. Yes ☒
No ☐

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule
12b-2 of the Exchange Act.

(Check One): Large accelerated filer ☐
Accelerated filer ☒ Non-accelerated ☐
Smaller reporting company ☐

Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐
No ☒

The aggregate market value of the voting
and non-voting common equity held by non-affiliates at March 31, 2015, the last business day of the registrant’s most recently
completed second fiscal quarter, was $65,938,100 (based on the closing price of the registrant’s common stock on the NASDAQ
Capital Market on such date). Shares of common stock held by each executive officer and director and by each person who owns 10%
or more of the outstanding common stock of the registrant have been excluded in that such person might be deemed to be an affiliate.
This determination of affiliate status might not be conclusive for other purposes.

At December 1, 2016, the registrant had
32,076,396 shares of common stock outstanding.

DOCUMENTS INCORPORATED
BY REFERENCE

None.











EXPLANATORY NOTE



This Amendment No. 1 (this “Amendment”)
to the Annual Report on Form 10-K for the fiscal year ended September 30, 2015 of Ohr Pharmaceutical, Inc., as filed with the Securities
and Exchange Commission on December 14, 2015 (the “Original Form 10-K”), is being filed for the sole purpose of filing
a revised consent of independent registered public accounting firm as Exhibit 23.1



This Amendment speaks as of the original filing
date of the Original Form 10-K, does not reflect events that may have occurred subsequent to the original filing date and does
not modify or update in any way disclosures made in the Original Form 10-K.



2







Part IV

|ITEM 15 | EXHIBITS, FINANCIAL STATEMENT SCHEDULES
|------- | ---------------------------------------

(a)(3)

|Exhibit
Number |  | Description of Exhibit                                   |  | The filings referencedfor incorporation by referenceare Ohr Pharmaceutical, Inc.(File No. 001-35963)
|-------------- |  | -------------------------------------------------------- |  | ----------------------------------------------------------------------------------------------------
|23.1           |  | Consent of Independent Registered Public Accounting Firm |  | Filed herewith                                                                                      
|               |  |                                                          |  |                                                                                                     
|31.1           |  | Section 302 Certification of Chief Executive Officer     |  | Filed herewith                                                                                      
|               |  |                                                          |  |                                                                                                     
|32.2           |  | Section 302 Certification of Chief Financial Officer     |  | Filed herewith                                                                                      



3







SIGNATURES



Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.





|                         | REGISTRANT:             
|------------------------ | ------------------------
|                         | OHR PHARMACEUTICAL, INC.
|                         |                         
|Dated:  December 7, 2016 | By:                     
|                         |                         
|                         |                         
|Dated:  December 7, 2016 | By:                     
|                         |                         
|                         |                         



Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.



|Dated:  December 7, 2016 | By: | /s/ JASON SLAKTER          
|------------------------ | --- | ---------------------------
|                         |     | Jason Slakter, Director    
|                         |     |                            
|Dated:  December 7, 2016 | By: | *                          
|                         |     | Ira Greenstein, Director   
|                         |     |                            
|Dated:  December 7, 2016 | By: | *                          
|                         |     | Orin Hirschman, Director   
|                         |     |                            
|Dated:  December 7, 2016 | By: | *                          
|                         |     | June Almenoff, Director    
|                         |     |                            
|Dated:  December 7, 2016 | By: | *                          
|                         |     | Thomas Riedhammer, Director







|*By: | /s/ Sam Backenroth | December 7, 2016
|---- | ------------------ | ----------------
|     | Sam Backenroth     |                 
|     | Attorney-In-Fact   |                 







4